Vladimir I. Razinkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vladimir I. Razinkov has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Gerald W. Becker
Drug Product Technologies, Amgen Inc., Seattle, WA, USA
6 shared publicationsFeng He
Process & Product Development, Amgen Inc., Seattle, Washington 98119, USA
4 shared publicationsLinda O. Narhi
Process & Product Development, Amgen Inc., Thousand Oaks, California 91320
4 shared publicationsMichael J. Treuheit
Drug Product Technologies, Amgen Inc., Thousand Oaks, CA, USA
4 shared publicationsLarysa Alekseychyk
Drug Product Technologies, Amgen, Thousand Oaks 91320
3 shared publicationsCheng Su
Biostatistics, Amgen Inc., San Francisco, CA, USA
2 shared publications
Latest Publications
- 1 February 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (2) , 738-745
Resolving Liquid-Liquid Phase Separation for a Peptide Fused Monoclonal Antibody by Formulation Optimization
- 1 February 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (2) , 738-745
Resolving Liquid-Liquid Phase Separation for a Peptide Fused Monoclonal Antibody by Formulation Optimization
- Open Access
- 1 September 2017
- Published by Elsevier in SLAS Discovery
- Vol. 22 (8) , 1044-1052
High-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations
- 1 September 2017
- Published by Elsevier in SLAS Discovery
- Vol. 22 (8) , 1044-1052
Open AccessHigh-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations
- Open Access
- 1 April 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (4) , 468-483
Accelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities: Review of Methods and Tools
- 1 April 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (4) , 468-483
Open AccessAccelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities: Review of Methods and Tools
- Open Access
- 1 October 2014
- Published by Elsevier in SLAS Discovery
- Vol. 19 (9) , 1290-1301
High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations
- 1 October 2014
- Published by Elsevier in SLAS Discovery
- Vol. 19 (9) , 1290-1301
Open AccessHigh-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations
- 1 March 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 10 (1) , 59-70
Methods of High Throughput Biophysical Characterization in Biopharmaceutical Development
Discovery and successful development of biopharmaceutical products depend on a thorough characterization of the molecule both before and after formulation. Characterization of a formulated biotherapeutic, typically a protein or large peptide, requires a rigorous assessment of the molecule’s physical stability. Stability of a biotherapeutic includes not only chemical stability, i.e., degradation of the molecule to form undesired modifications, but also structural stability, including the formation of aggregates. In this review, high throughput biophysical characterization techniques are described according to their specific applications during biopharmaceutical discovery, development and manufacturing. The methods presented here are classified according to these attributes, and include spectroscopic assays based on absorbance, polarization, intrinsic and extrinsic fluorescence, surface plasmon resonance instrumentation, calorimetric methods, dynamic and static light scattering techniques, several visible particle counting and sizing methods, new viscosity assay, based on light scattering and mass spectrometry. Several techniques presented here are already implemented in industry; but, many high throughput biophysical methods are still in the initial stages of implementation or even in the prototype stage. Each technique in this report is judged by the specific application of the method through the biopharmaceutical development process.
- 1 March 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 10 (1) , 59-70
Methods of High Throughput Biophysical Characterization in Biopharmaceutical Development
Discovery and successful development of biopharmaceutical products depend on a thorough characterization of the molecule both before and after formulation. Characterization of a formulated biotherapeutic, typically a protein or large peptide, requires a rigorous assessment of the molecule’s physical stability. Stability of a biotherapeutic includes not only chemical stability, i.e., degradation of the molecule to form undesired modifications, but also structural stability, including the formation of aggregates. In this review, high throughput biophysical characterization techniques are described according to their specific applications during biopharmaceutical discovery, development and manufacturing. The methods presented here are classified according to these attributes, and include spectroscopic assays based on absorbance, polarization, intrinsic and extrinsic fluorescence, surface plasmon resonance instrumentation, calorimetric methods, dynamic and static light scattering techniques, several visible particle counting and sizing methods, new viscosity assay, based on light scattering and mass spectrometry. Several techniques presented here are already implemented in industry; but, many high throughput biophysical methods are still in the initial stages of implementation or even in the prototype stage. Each technique in this report is judged by the specific application of the method through the biopharmaceutical development process.
- 1 December 2011
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 100 (12) , 5126-5141
High‐Throughput Assessment of Thermal and Colloidal Stability Parameters for Monoclonal Antibody Formulations
- 1 December 2011
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 100 (12) , 5126-5141
High‐Throughput Assessment of Thermal and Colloidal Stability Parameters for Monoclonal Antibody Formulations
- 1 April 2011
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 100 (4) , 1330-1340
Screening of Monoclonal Antibody Formulations Based on High-Throughput Thermostability and Viscosity Measurements: Design of Experiment and Statistical Analysis
- 1 April 2011
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 100 (4) , 1330-1340
Screening of Monoclonal Antibody Formulations Based on High-Throughput Thermostability and Viscosity Measurements: Design of Experiment and Statistical Analysis
- 1 June 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (6) , 2598-2608
Detection of IgG Aggregation by a High Throughput Method Based on Extrinsic Fluorescence
- 1 June 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (6) , 2598-2608
Detection of IgG Aggregation by a High Throughput Method Based on Extrinsic Fluorescence
- 1 April 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (4) , 1707-1720
High throughput thermostability screening of monoclonal antibody formulations
- 1 April 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (4) , 1707-1720
High throughput thermostability screening of monoclonal antibody formulations